Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors or Progressive or Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer
Phase I/II Study of Erlotinib (TARCEVA) and Cetuximab (ERBITUX) in Advanced Solid Tumors, With Emphasis on Non Small Cell Lung Cancer (NSCLC)
Status: Archived
University of California Davis Cancer Center
mi
from
Sacramento, CA
Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors or Progressive or Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer
Phase I/II Study of Erlotinib (TARCEVA) and Cetuximab (ERBITUX) in Advanced Solid Tumors, With Emphasis on Non Small Cell Lung Cancer (NSCLC)
Status: Archived
Updated: 1/1/1970
University of California Davis Cancer Center
mi
from
Sacramento, CA
Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors
A Phase I Trial of Nelfinavir (Viracept®) in Adults With Solid Tumors
Status: Archived
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors
A Phase I Trial of Nelfinavir (Viracept®) in Adults With Solid Tumors
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
mi
from
Bethesda, MD
Identification of Key Blood Molecular Markers for Immunotherapy
Identification of Key Blood Molecular Markers for Immunotherapy
Status: Archived
Stanford University School of Medicine
mi
from
Stanford, CA
Identification of Key Blood Molecular Markers for Immunotherapy
Identification of Key Blood Molecular Markers for Immunotherapy
Status: Archived
Updated: 1/1/1970
Stanford University School of Medicine
mi
from
Stanford, CA
Phase I/II Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers
Phase I/II Study of LBH589 in Combination With Erlotinib for Advanced Aerodigestive Tract Cancers (CLBH5889CUS11T)
Status: Archived
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Phase I/II Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers
Phase I/II Study of LBH589 in Combination With Erlotinib for Advanced Aerodigestive Tract Cancers (CLBH5889CUS11T)
Status: Archived
Updated: 1/1/1970
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
A Phase I Study of 1-methyl-D-tryptophan (D-1MT) in Patients With Relapsed or Refractory Solid Tumors
Status: Archived
Vanderbilt University Medical Center
mi
from
Ventura, CA
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
A Phase I Study of 1-methyl-D-tryptophan (D-1MT) in Patients With Relapsed or Refractory Solid Tumors
Status: Archived
Updated: 1/1/1970
Vanderbilt University Medical Center
mi
from
Ventura, CA
Safety Study of XL147 in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 in Combination With Paclitaxel and Carboplatin in Subjects With Solid Tumors
Status: Archived
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Safety Study of XL147 in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 in Combination With Paclitaxel and Carboplatin in Subjects With Solid Tumors
Status: Archived
Updated: 1/1/1970
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Safety Study of XL147 in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 in Combination With Paclitaxel and Carboplatin in Subjects With Solid Tumors
Status: Archived
University of Wisconsin-Madison, Department of Dermatology
mi
from
Madison, WI
Safety Study of XL147 in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 in Combination With Paclitaxel and Carboplatin in Subjects With Solid Tumors
Status: Archived
Updated: 1/1/1970
University of Wisconsin-Madison, Department of Dermatology
mi
from
Madison, WI
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Northwest Alabama Cancer Center, PC
mi
from
Muscle Shoals, AL
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Northwest Alabama Cancer Center, PC
mi
from
Muscle Shoals, AL
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Lancanster Cancer Center
mi
from
Lancaster, PA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Lancanster Cancer Center
mi
from
Lancaster, PA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
North Valley Hematology/Oncology Medical Group
mi
from
Mission Hills, CA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
North Valley Hematology/Oncology Medical Group
mi
from
Mission Hills, CA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Medical Oncology Care Associates
mi
from
Orange, CA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Medical Oncology Care Associates
mi
from
Orange, CA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Ajay Verma, MD
mi
from
Redding, CA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Ajay Verma, MD
mi
from
Redding, CA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Lee Cancer Clinic
mi
from
Fort Myers, FL
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Lee Cancer Clinic
mi
from
Fort Myers, FL
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Alexian Brothers Medical Center, 800 Biesterfield Rd.
mi
from
Elk Grove Village, IL
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Alexian Brothers Medical Center, 800 Biesterfield Rd.
mi
from
Elk Grove Village, IL
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Clarian Arnett Cancer Care
mi
from
Lafayette, IN
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Clarian Arnett Cancer Care
mi
from
Lafayette, IN
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Medical Associates Clinic, PC
mi
from
Dubuque, IA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Medical Associates Clinic, PC
mi
from
Dubuque, IA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Kentucky Cancer Clinic
mi
from
Hazard, KY
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Kentucky Cancer Clinic
mi
from
Hazard, KY
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Kentuckiana Cancer Institute, PLLC
mi
from
Louisville, KY
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Kentuckiana Cancer Institute, PLLC
mi
from
Louisville, KY
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Medical Oncology LLC
mi
from
Baton Rouge, LA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Medical Oncology LLC
mi
from
Baton Rouge, LA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
West Michigan Regional Cancer & Blood Center
mi
from
Freesoil, MI
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
West Michigan Regional Cancer & Blood Center
mi
from
Freesoil, MI
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Community Cancer Care Specialists
mi
from
Mount Clemens, MI
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Community Cancer Care Specialists
mi
from
Mount Clemens, MI
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Huron Medical Center
mi
from
Port Huron, MI
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Huron Medical Center
mi
from
Port Huron, MI
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
St Louis Center for Clinical Studies
mi
from
St Louis, MO
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
St Louis Center for Clinical Studies
mi
from
St Louis, MO
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Nebraska Hematology-Oncology, PC
mi
from
Lincoln, NE
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Nebraska Hematology-Oncology, PC
mi
from
Lincoln, NE
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Southern Nevada Cancer Research Center
mi
from
Las Vegas, NV
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Southern Nevada Cancer Research Center
mi
from
Las Vegas, NV
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Summa Health System
mi
from
Akron, OH
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Summa Health System
mi
from
Akron, OH
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Hematology Associates
mi
from
Bedford, OH
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Hematology Associates
mi
from
Bedford, OH
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Oncology Hematology Care
mi
from
Cincinnati, OH
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Oncology Hematology Care
mi
from
Cincinnati, OH
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Signal Point Clinical Research Center, LLC
mi
from
Middletown, OH
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Signal Point Clinical Research Center, LLC
mi
from
Middletown, OH
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Gettysburg Cancer Center
mi
from
Gettysburg, PA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Gettysburg Cancer Center
mi
from
Gettysburg, PA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Landmark Medical Center
mi
from
Woonsocket, RI
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Landmark Medical Center
mi
from
Woonsocket, RI
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Cancer Center Associates of Carolina
mi
from
Aiken, SC
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Cancer Center Associates of Carolina
mi
from
Aiken, SC
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
McLeod Cancer & Blood Center
mi
from
Johnson City, TN
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
McLeod Cancer & Blood Center
mi
from
Johnson City, TN
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Tennessee Cancer Specialists
mi
from
Knoxville, TN
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Tennessee Cancer Specialists
mi
from
Knoxville, TN
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Lone Star Oncology - Austin
mi
from
Austin, TX
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Lone Star Oncology - Austin
mi
from
Austin, TX
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Hope Oncology
mi
from
Richardson, TX
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Hope Oncology
mi
from
Richardson, TX
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Masoom Kandahari, MD, PC
mi
from
Woodbridge, VA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Masoom Kandahari, MD, PC
mi
from
Woodbridge, VA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Olympic Hematology and Oncology
mi
from
Bremerton, WA
Phase II Avastin Trial for Stage IIIB/IV NSCLC
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Olympic Hematology and Oncology
mi
from
Bremerton, WA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Arizona Cancer Center, University of Arizona
mi
from
Tucson, AZ
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Arizona Cancer Center, University of Arizona
mi
from
Tucson, AZ
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
USC Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
USC Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Tibotec Therapeutics - Division of Ortho Biotech Products, LP
mi
from
Marysville, CA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Tibotec Therapeutics - Division of Ortho Biotech Products, LP
mi
from
Marysville, CA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Valley Medical Oncology Consultants - Pleasanton
mi
from
Pleasanton, CA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Valley Medical Oncology Consultants - Pleasanton
mi
from
Pleasanton, CA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
University of California Davis Cancer Center
mi
from
Sacramento, CA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
University of California Davis Cancer Center
mi
from
Sacramento, CA
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
University of Colorado, Boulder
mi
from
Boulder, CO
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
University of Colorado, Boulder
mi
from
Boulder, CO
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Shaw Regional Cancer Center
mi
from
Edwards, CO
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Shaw Regional Cancer Center
mi
from
Edwards, CO
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Valley View Hospital Cancer Center
mi
from
Glenwood Springs, CO
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Valley View Hospital Cancer Center
mi
from
Glenwood Springs, CO
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Montrose Memorial Hospital Cancer Center
mi
from
Montrose, CO
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Montrose Memorial Hospital Cancer Center
mi
from
Montrose, CO
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
mi
from
Hartford, CT
Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Status: Archived
Updated: 1/1/1970
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
mi
from
Hartford, CT